Therefore, the combined usage of AKT inhibitors and small-molecule inhibitors targeting fatty acid metabolism might represent a novel therapeutic strategy to improve clinical outcomes in ccRCC. The gene discussed is AKT1; the disease is nonpapillary renal cell carcinoma.